Livagen is strictly for laboratory research and is commonly employed in the following investigational areas:

Chromatin Remodeling and Epigenetics

Livagen is a primary reagent for studying the “opening” of aged chromatin. Researchers use it to observe the decondensation of heterochromatin and the activation of Nucleolar Organizer Regions (NORs) in lymphocytes from elderly subjects, measuring the subsequent changes in transcriptional activity.

Enkephalinase Inhibition and Pain Signaling

Studies involving human serum investigate Livagen’s ability to inhibit enkephalin-degrading enzymes (such as aminopeptidase N). This application focuses on understanding how peptide bioregulators can influence the half-life of endogenous opioids and modulate pain-signaling pathways.

Digestive Enzyme Regulation

Livagen is used to investigate the regulation of digestive physiology. In rat models of different ages, it is administered to measure changes in the activity of key digestive enzymes (e.g., pepsin, trypsin, amylase) in the gastrointestinal tract and pancreas.

Immune System Morphology

In hypophysectomized avian models (birds with the pituitary gland removed), Livagen is utilized to study the structural recovery of the thymus. Researchers quantify changes in cortical and medullary thickness to assess the peptide’s restorative effects on immunosenescence.

Pathway / Mechanistic Context

The primary mechanism of action for Livagen in research settings involves chromatin modification and enzyme inhibition.

• Chromatin Decondensation: Livagen interacts with histone proteins or DNA-associated factors to reduce the compaction of chromatin. This allows transcriptional machinery access to previously silenced genes, particularly ribosomal RNA genes.
• Enzyme Inhibition: It acts as an inhibitor of specific proteases, such as enkephalinases, preserving the stability of regulatory peptides like enkephalins.
• Gene Activation: By increasing the number of active Nucleolar Organizer Regions (NORs), Livagen enhances protein synthesis capacity in aged cells.

Preclinical Research Summary

Published preclinical literature documents investigations of Livagen across multiple experimental models:

• Atherosclerosis and Genomic Instability: Research indicates that Livagen can reduce genomic instability in lymphocyte cultures from patients with atherosclerosis, suggesting a protective role against age-related DNA damage.
• Thymic Restoration: In immunodeficient models, Livagen treatment was observed to normalize the morphological structure of the thymus, countering the atrophy typically seen with aging or pituitary loss.
• Enzymatic Profiles: Studies show that Livagen influences the activity of digestive enzymes in a specific manner, increasing activity in older animals while modulating it in younger ones, indicating an age-dependent regulatory function.

Form & Analytical Testing

This material is produced via robust solid-phase peptide synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain peptide integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Kuznik, B., et al. (2020). [The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]. Advances in gerontology.
• Timofeeva, N. M., et al. (2005). [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. Advances in gerontology.
• Kost, N., et al. (2003). [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. Izvestiia Akademii nauk. Seriia biologicheskaia.
• Kost, N. V., et al. (2003). Springer Science and Business Media LLC. https://doi.org/10.1023/a:1024809822681
• (2023). EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE ‘OLD’ CHROMATIN. Georgian medical news.
• Lezhava, T., et al. (2022). Epigenetic Variations in Chromatin Caused by the Combination of Bioregulators with Heavy Metals During Aging. Springer Science and Business Media LLC. https://doi.org/10.1007/s10989-022-10427-9
• (2014). [Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives]. Georgian medical news.
• Pateyk, A. V., et al. (2013). Effect of Peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the Morphology of the Thymus in Hypophysectomized Young and Old Birds. Springer Science and Business Media LLC. https://doi.org/10.1007/s10517-013-2029-0
• Dzhokhadze, T. A., et al. (2014). [Genomic instability in atherosclerosis]. Georgian

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.